Cystic Fibrosis Foundation

Cystic Fibrosis Foundation

Raises funds and coordinates CF research

Overview

The Cystic Fibrosis Foundation is a nonprofit nonprofit organization that funds and coordinates medical research and development to treat and cure cystic fibrosis. It does not sell a product; instead, it supports scientists, clinical trials, and patient programs to accelerate discovery and access to therapies. Its work includes funding research, guiding clinical development, and partnering with the CF community to translate scientific advances into treatments that improve health and extend life. The Foundation differentiates itself by its global leadership, large-scale funding, and close collaboration with patients and researchers, which have led to multiple approved CF therapies. Its goal is to enable every person with cystic fibrosis to live a long, healthy life by delivering a cure and reducing the disease’s burden.

About Cystic Fibrosis Foundation

Simplify's Rating
Why Cystic Fibrosis Foundation is rated
B
Rated A on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Social Impact

Healthcare

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Bethesda, Maryland

Founded

1955

Get referred to Cystic Fibrosis Foundation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CFF’s August 2026 ReCode funding expands gene-editing delivery work for lung cells.
  • June 2026 Teen Advocacy Day mobilized 130 advocates and 6,400 messages across Congress.
  • The 2026 annual report says full NIH funding preserves another year of CF science.

What critics are saying

  • NIH funding dominates CF discovery; Congress only secured 2026 funding, not 2027.
  • CFTR modulators lengthen lives, increasing costly adult-care demand that strains care-network redesign.
  • If venture philanthropy stops producing breakthroughs, donors and partners lose faith in CFF’s model.

What makes Cystic Fibrosis Foundation unique

  • CFF’s 2026-2030 plan targets genetic cures, care delivery, and community mobilization.
  • Its venture philanthropy model has produced 13x 2026 operating-budget reserves.
  • CFF funds niche CF programs biotech ignores, including ReCode, Prime Medicine, and Antiverse.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

401(k) Retirement Plan

401(k) Company Match

Stock Options

Company Equity

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Discounts

Meal Benefits

Legal Services

Pet Insurance

Commuter Benefits

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Employee Referral Bonus

Performance Bonus

Profit Sharing

Paid Time Off

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%
FinSMEs
Aug 6th, 2026
ReCode Therapeutics receives investment from Cystic Fibrosis Foundation for gene editing therapy

ReCode Therapeutics, a Menlo Park, California-based clinical-stage genetic medicines company, received an undisclosed investment from the Cystic Fibrosis Foundation. The funding will support a research collaboration to develop a novel gene editing therapy designed to correct mutations in the CFTR gene, the underlying genetic cause of cystic fibrosis. Led by CEO Heather Clark, ReCode uses its proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform to enable precise delivery of genetic medicines directly to organs, tissues, and cells implicated in disease. The technology aims to improve efficacy and potency of mRNA and gene correction therapeutics.

Cystic Fibrosis Foundation
Jun 29th, 2026
130+ Advocates Urge Congress to Protect NIH Funding During 18th Annual Teen Advocacy Day

130+ advocates urge Congress to protect NIH funding during 18th annual Teen Advocacy Day. In more than 120 meetings, advocates called on lawmakers to increase funding for the NIH and protect the future of cystic fibrosis research. On June 25, more than 130 advocates from across the country, including more than two dozen living with cystic fibrosis, met with members of Congress and their staff during the Cystic Fibrosis Foundation's annual Teen Advocacy Day, urging them to support increased funding to the National Institutes of Health and protect funding for the vital research driving breakthroughs toward a cure for CF. The event, now in its 18th year, brings together teens, young adults, and families in the CF community to speak up for policies that impact their loved ones living with cystic fibrosis. "The remarkable progress we've seen in cystic fibrosis is driven by sustained investment in science, including a robust commitment to fund NIH and fund essential research," said Mary Dwight, senior vice president and chief policy and advocacy officer of the Cystic Fibrosis Foundation. "We're grateful a new generation of advocates is stepping forward to protect that innovation and continued progress in CF research. Today's advocates' voices are critical to ensuring we continue moving closer to a cure for every person with CF." Alongside advocates on Capitol Hill, more than 1,300 community members from all 50 states participated in the Foundation's Online Day of Action. Together, they sent more than 6,400 messages to lawmakers, amplifying the community's collective voice and reinforcing the urgent need to sustain research funding. Previous Teen Advocacy Day advocates Michael Woody, a young adult living with CF, and Bailee Goldman and Gracie Salema, siblings of people with CF, served as Teen Advocacy Day interns. During their tenure, the group lent their expertise to help craft the event's program and connect with virtual and in-person attendees. Interested in joining the effort to maintain critical CF research? Sign up for the Foundation's advocacy alerts to stay informed and take action. Its Advocacy Work Milestones III Raises More Than $250M to Advance a Cure and Innovative CF Care CF Foundation Commits Up to $13 Million in Additional Funding to Advance Potential Splicing Mutation Treatment FDA Approves Expansion of Two CFTR Modulator Therapies to Additional Rare CF Mutations You might also be interested in...

Third News
Jun 16th, 2026
SpliSense secures $13M from Cystic Fibrosis Foundation to advance SPL84 phase 2b trials

SpliSense, a biotechnology firm specialising in RNA-based therapies for pulmonary diseases, has secured up to $13 million in funding from the Cystic Fibrosis Foundation to advance Phase 2b clinical trials of its investigational drug SPL84 for cystic fibrosis treatment. The funding follows successful Phase 2a results showing a 10 percentage point improvement in lung function in nearly 70% of patients compared to placebo, marking the first clinical proof-of-concept for an inhaled antisense oligonucleotide therapy in a respiratory condition. The Phase 2b study will evaluate SPL84's safety and efficacy in approximately 40 patients with the 3849+10kb C→T mutation across sites in the United States, Europe and Israel, with topline results expected in the second half of 2025.

Newz
Mar 24th, 2026
American Airlines leads fundraising at Celebrity Ski to support Cystic Fibrosis research.

American Airlines leads fundraising at Celebrity Ski to support Cystic Fibrosis research. Table of Contents The Celebrity Ski weekend in Beaver Creek, Colorado, brought together airline staff, corporate partners and community supporters for a concentrated burst of fundraising and awareness. Over the course of the retreat-style event, participants helped raise more than $1.6 million to benefit the Cystic Fibrosis Foundation. Organizers emphasized both the social and scientific impact of the effort, noting that the proceeds will support ongoing clinical research and patient care initiatives focused on improving outcomes for people living with cystic fibrosis, a genetic disorder that primarily affects the lungs and digestive system. More than 425 attendees and volunteers joined the weekend of events, which featured familiar faces from sports and entertainment alongside airline employees. Notable participants included Carli Lloyd, Alexi Lalas and Mark Ingram, and a live performance curated by Warner Records spotlighted artist Michael Marcagi. In addition to on-slope activities and concerts, supporters contributed through silent auctions, sponsorship packages and mile-based donations, continuing traditions that have made the event a cornerstone of corporate philanthropy tied to the fight against CF. Pubblicità Event highlights and community impact. The weekend combined recreational programming with intentional fundraising, bringing attention to both the work of clinicians and the lived experience of people with CF. Attendees took part in a variety of activities meant to strengthen community ties and fundraise, while the event itself amplified the Foundation's research priorities. Organizers noted that the energy generated by volunteers and celebrity guests translated directly into financial support for trials, therapies and care centers. The tally of more than $1.6 million will be directed into the Foundation's research portfolio, bolstering efforts to develop new treatments and move closer to a cure. Notable participants and programming. High-profile guests helped elevate the weekend's visibility, attracting additional donors and media attention. The mix of professional athletes, entertainers and airline personnel created a broad base of engagement that extended beyond the slopes. Programming included participant-driven fundraisers, performances and networking sessions that highlighted how corporate resources can amplify nonprofit missions. The presence of celebrity backers served as a catalyst to drive both donations and public awareness for the Cystic Fibrosis Foundation. How donations were collected. Fundraising methods combined traditional giving with creative corporate mechanisms. In addition to auction and sponsorship revenue, American Airlines leveraged its loyalty ecosystem by contributing hundreds of millions of AAdvantage miles over time to support similar fundraising efforts nationwide. This event also used direct financial gifts and in-kind support to cover logistical costs, maximizing the amount available for research and patient care. Such blended approaches have helped sustain the Celebrity Ski event over four decades. Pubblicità Longstanding partnerships and leadership. American's involvement in the Celebrity Ski program is part of a much larger philanthropic relationship with the CF community. The airline has contributed to more than $50 million in support of the Foundation across multiple initiatives, underscoring a long-term commitment to advancing treatments and care. Company leaders described the weekend as an example of team members and partners working together to make a measurable difference outside of the day-to-day travel business. Foundation leadership characterized American as a vital, long-running corporate supporter whose backing has directly supported scientific breakthroughs. About the organizations. American Airlines operates a global network and is powered by a large workforce of aviation professionals who emphasize customer service and community engagement. The airline flies thousands of daily flights to hundreds of destinations worldwide and serves millions of customers annually. As a company, American highlights milestones in innovation and continues to invest in both customer experience and charitable activities; it also marks its centennial year in 2026. The airline is a founding member of the oneworld alliance, whose members serve more than 900 destinations around the globe. The Cystic Fibrosis Foundation leads global efforts to accelerate research into treatments and ultimately a cure. Based in Bethesda, Md., the Foundation funds more CF research than any other organization and supports a national network of accredited care centers recognized by the National Institutes of Health as a model for chronic disease care. Much of the progress in current CF therapies has been made possible because of Foundation-funded science. The organization operates as a donor-supported nonprofit; more information is available at cff.org.

EPR Network LLC
Mar 24th, 2026
American Airlines brings together celebrities and communities in Colorado to support Cystic Fibrosis research.

American Airlines brings together celebrities and communities in Colorado to support Cystic Fibrosis research. (NEWS) FORT WORTH, TX, United States, 2026-Mar-24 - /Travel PR News/ - A long-running partnership between American Airlines and the Cystic Fibrosis Foundation took center stage once again in Colorado, as the airline and its partners gathered for the 41st Celebrity Ski event in Beaver Creek - a fundraising initiative that blends community engagement with efforts to advance medical research. The annual event brought together airline employees, industry partners and high-profile guests for a weekend of activities on the slopes, all aimed at supporting research into cystic fibrosis, a genetic condition that affects the lungs and other organs. According to details shared in official updates, the initiative is part of a broader commitment by American Airlines to support healthcare causes beyond its core travel operations. A decades-long fundraising effort Over the years, the airline has contributed more than $50 million toward cystic fibrosis research and care, making it one of the foundation's longest-standing corporate supporters. The Celebrity Ski event has become a cornerstone of that relationship, serving as both a fundraising platform and a way to raise awareness about the disease. This year's gathering welcomed more than 400 participants and volunteers, alongside a number of sports and entertainment figures, including Carli Lloyd, Alexi Lalas, and Mark Ingram. Attendees also took part in live entertainment events, adding a social and cultural dimension to the weekend. Supporting research and patient care The Cystic Fibrosis Foundation remains a leading force in funding research into treatments and potential cures, with many existing therapies linked to its support. According to the organisation, advances in treatment have helped improve life expectancy for people living with the condition, reflecting decades of sustained investment in research and care. American Airlines' involvement extends beyond the ski event itself. The airline has also supported fundraising initiatives through the donation of AAdvantage loyalty miles and broader corporate contributions, helping to expand the reach of the foundation's work. Travel industry engagement beyond transportation The continued partnership highlights a wider trend in the aviation sector, where airlines are increasingly aligning with social and healthcare initiatives as part of their broader corporate responsibility strategies. By leveraging their networks, customer base and brand visibility, carriers are playing a role in supporting causes that extend beyond travel. As the airline approaches its centennial year in 2026, initiatives such as the Celebrity Ski event illustrate how long-term partnerships can contribute to both community engagement and global health efforts - demonstrating the evolving role of airlines in supporting causes that resonate with their passengers and employees alike.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Cystic Fibrosis Foundation right now.

Find jobs on Simplify and start your career today

We update Cystic Fibrosis Foundation's jobs every few hours, so check again soon! Browse all jobs →